COVID-19与妊娠研究更新
妊娠期生理、机械和免疫改变可能影响COVID-19易感性和严重程度,但数据不足以确定妊娠是否增加SARS-CoV-2感染易感性。数据支持妊娠是COVID-19重症的危险因素,美国CDC监测系统报告孕妇更易入住ICU、需要有创通气、需要ECMO和死亡。SARS-CoV-2宫内传播已有记录但罕见,可能与低病毒血症和胎盘ACE2与TMPRSS2共表达降低有关。证据积累显示妊娠期SARS-CoV-2感染与子痫前期、早产和死产等不良妊娠结局相关,尤其在重症COVID-19孕妇中。大流行对医疗系统的影响也导致死产和孕产妇死亡增加。美国所有3种COVID-19疫苗均可用于孕妇或哺乳期人群,无疫苗类型偏好,但需更多出生结局数据。
要点
- 妊娠是COVID-19重症的危险因素,孕妇更易入住ICU、需要有创通气、ECMO和死亡。
- SARS-CoV-2宫内传播罕见,可能与低病毒血症和胎盘ACE2与TMPRSS2共表达降低有关。
- 妊娠期SARS-CoV-2感染与子痫前期、早产和死产相关,尤其重症病例。
核心结论
- 数据支持妊娠是COVID-19重症的危险因素,但不足以确定妊娠是否增加SARS-CoV-2感染易感性。
- SARS-CoV-2宫内传播罕见,妊娠期感染与子痫前期、早产和死产等不良结局相关。
- 美国所有3种COVID-19疫苗均可用于孕妇或哺乳期人群,无疫苗类型偏好。
研究设计与样本
- 本文为综述,基于美国CDC COVID-19监测系统等证据汇总妊娠与COVID-19相关数据。
主要发现
- 美国CDC监测系统报告孕妇比非妊娠育龄女性更易入住ICU、需要有创通气、需要ECMO和死亡。
- SARS-CoV-2宫内传播已有记录但罕见,可能与低病毒血症和胎盘ACE2与TMPRSS2共表达降低有关。
- 妊娠期SARS-CoV-2感染与子痫前期、早产和死产相关,尤其在重症COVID-19孕妇中。
- 大流行对医疗系统的影响导致死产和孕产妇死亡增加,可能扩大 disparities 并逆转近期母婴健康改善。
关键数值与推荐
- 美国所有3种COVID-19疫苗均可用于孕妇或哺乳期人群,无疫苗类型偏好。
- 妊娠期疫苗安全数据快速积累,未检测到安全信号,但需更多出生结局信息,尤其早期妊娠接种者。
临床怎么用
- 应将孕妇视为COVID-19重症高风险人群,加强监测和重症预警。
- 孕妇和哺乳期人群可接种美国所有3种COVID-19疫苗,无需偏好特定类型。
- 对妊娠期SARS-CoV-2感染需关注子痫前期、早产和死产等不良结局,尤其重症病例。
局限性
- 缺乏可比发病率数据,难以区分易感性与暴露风险差异。
- 妊娠期疫苗安全数据仍在积累,出生结局信息尤其早期妊娠接种者需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Physiological, mechanical, and immunologic alterations in pregnancy could potentially affect the susceptibility to and the severity of COVID-19 during pregnancy. Owing to the lack of comparable incidence data and the challenges with disentangling differences in the susceptibility from different exposure risks, the data are insufficient to determine whether pregnancy increases the susceptibility to SARS-CoV-2 infection. The data support pregnancy as a risk factor for severe disease associated with COVID-19; some of the best evidence comes from the United States Centers for Disease Control and Prevention COVID-19 surveillance system, which reported that pregnant persons were more likely to be admitted to an intensive care unit, require invasive ventilation, require extracorporeal membrane oxygenation, and die than nonpregnant women of reproductive age. Although the intrauterine transmission of SARS-CoV-2 has been documented, it appears to be rare. It is possibly related to low levels of SARS-CoV-2 viremia and the decreased coexpression of angiotensin-converting enzyme 2 and transmembrane serine protease 2 needed for SARS-CoV-2 entry into cells in the placenta. Evidence is accumulating that SARS-CoV-2 infection during pregnancy is associated with a number of adverse pregnancy outcomes including preeclampsia, preterm birth, and stillbirth, especially among pregnant persons with severe COVID-19 disease. In addition to the direct impact of COVID-19 on pregnancy outcomes, there is evidence that the pandemic and its effects on healthcare systems have had adverse effects such as increased stillbirths and maternal deaths on the pregnancy outcomes. These trends may represent widening disparities and an alarming reversal of recent improvements in maternal and infant health. All the 3 COVID-19 vaccines currently available in the United States can be administered to pregnant or lactating persons, with no preference for the vaccine type. Although the safety data in pregnancy are rapidly accumulating and no safety signals in pregnancy have been detected, additional information about the birth outcomes, particularly among persons vaccinated earlier in pregnancy, are needed.
引用
- Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2021. PMID: 34534497. doi:10.1016/j.ajog.2021.08.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。